Acalabrutinib [1], antacids ---> SmPC of [1] of EMA
Acalabrutinib solubility decreases with increasing pH. For use with antacids, the interval between taking the medicinal product should be at least 2 hours
Acarbose, antacids
The co-administration may reduce the effect of acarbose and should not therefore be taken concomitantly
ACE inhibitors, antacids ---> SmPC of [trandolapril/verapamil] of eMC
Antacids induce decreased bioavailability of ACE inhibitors.
Acemetacine, antacids
Decreased absorption of NSAID
Acenocoumarol, antacids
Antacids may enhance the anticoagulant effect of acenocoumarol
Acetylsalicylic acid [1], antacids ---> SmPC of [1] of eMC
Alkalizers of urine (eg antacids, citrates) - increased excretion of aspirin.
Alectinib [1], antacids ---> SmPC of [1] of EMA
Therefore, no dose adjustments are required when Alecensa is co-administered with proton pump inhibitors or other medicinal products which raise gastric pH (e.g. H2 receptor antagonists or antacids).
Alendronate, antacids ---> SmPC of [alendronic acid/colecalciferol] of EMA
If taken at the same time, it is likely that calcium supplements and antacids will interfere with absorption of alendronate. Patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product
Alendronic acid, antacids ---> SmPC of [alendronic acid/colecalciferol] of EMA
If taken at the same time, it is likely that calcium supplements and antacids will interfere with absorption of alendronate. Patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product
Alendronic acid/colecalciferol [1], antacids ---> SmPC of [1] of EMA
If taken at the same time, it is likely that calcium supplements and antacids will interfere with absorption of alendronate. Patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product
Alfacalcidol, antacids
The concomitant use of alfacalcidol and antacids with magnesium may increase the risk of hypermagnesemia
Alimemazine [1], antacids ---> SmPC of [1] of eMC
The antacid can decrease the gastrointestinal absorption of phenothiazine
Allopurinol, antacids
The co-administration may decrease the gastrointestinal absorption of allopurinol. Separate administration by at least 3 hours
Almasilate, antacids
Antacids may modify the absorption of coadministered drugs. It is recommended to separate administration of both drugs by at least 2 hours
Alpelisib [1], antacids ---> SmPC of [1] of EMA
Alpelisib can be co-administered with acid-reducing agents, provided alpelisib is taken immediately after food
Amisulpride, antacids
Concomitant use of amisulpride with antacids which contain calcium or magnesium salts may decrease plasma concentrations of amisulpride
Amprenavir [1], antacids ---> SmPC of [1] of EMA
It is advisable not to take antacids at the same time as amprenavir, since its absorption may be impaired. It is recommended at least 1 hour apart to administer them
Amprenavir/ritonavir, antacids ---> SmPC of [amprenavir] of EMA
It is advisable not to take antacids at the same time as amprenavir, since its absorption may be impaired. It is recommended at least 1 hour apart to administer them
Antacids, anticholinergics
The co-administration may decrease the absorption of anticholinergic agent. The anticholinergic should be administered at least 1 hour before antacid
Antacids, ascorbic acid
The concomitant use of aluminium-containing antacids with ascorbic acid may increase the aluminium absorption and cause toxicity. The combination is not recommended
Antacids, atazanavir [2] ---> SmPC of [2] of EMA
Decreased atazanavir absorption. Atazanavir should be administered 2 hours before or 1 hour after antacid.
Antacids, atazanavir/cobicistat [2] ---> SmPC of [2] of EMA
Reduced plasma concentrations of atazanavir may be the consequence of increased gastric pH if antacids are administered with EVOTAZ. EVOTAZ should be administered 2 hours before or 1 hour after antacids
Antacids, azilsartan medoxomil [2] ---> SmPC of [2] of EMA
No clinically significant interactions have been reported in studies of azilsartan medoxomil or azilsartan given with amlodipine, antacids, chlortalidone, digoxin, fluconazole, glyburide, ketoconazole, metformin, and warfarin.
Antacids, azithromycin [2] ---> SmPC of [2] of eMC
Decreased peak serum concentrations of azithromycin. Azithromycin should be administered at least 1 hour before or 2 hours after antacid
Antacids, baloxavir [2] ---> SmPC of [2] of EMA
Products that contain polyvalent cations may decrease plasma concentrations of baloxavir. Xofluza should not be taken with products that contain polyvalent cations
Antacids, bazedoxifene ---> SmPC of [conjugated oestrogens/bazedoxifene] of EMA
There were no significant pharmacokinetic interactions between bazedoxifene and antacids with aluminium
Antacids, betaxolol
Take betaxolol 2 hours after the antacid
Antacids, bictegravir/emtricitabine/tenofovir alafenamide [2] ---> SmPC of [2] of EMA
Chelation with polyvalent cations. Biktarvy should be administered at least 2 hours before, or with food 2 hours after antacids containing magnesium and/or aluminium.
Antacids, biphosphonates
Decreased absorption of bisphosphonate. Administer on empty stomach at least 1 hour before or 1-2 hours after food.
Antacids, bisacodyl [2] ---> SmPC of [2] of eMC
The concomitant use of antacids may reduce the resistance of the coating of the tablets and result in dyspepsia and gastric irritation.
Antacids, bosutinib [2] ---> SmPC of [2] of EMA
Short-acting antacids should be considered as an alternative to PPIs and administration times of bosutinib and antacids should be separated (i.e. take bosutinib in the morning and antacids in the evening) whenever possible.
Antacids, breast-feeding
Caution should be exercised when prescribing to pregnant and lactating women.
Antacids, budesonide
The co-administration may decrease the absorption of budesonide. They should not be taken simultaneously, but at least 2 hours apart
Antacids, cabozantinib [2] ---> SmPC of [2] of EMA
No dose adjustment is indicated when gastric pH modifying agents (i.e., PPIs, H2 receptor antagonists, and antacids) are co-administered with cabozantinib
Antacids, calcitriol [2] ---> SmPC of [2] of eMC
Magnesium-containing drugs (e.g. antacids) may cause hypermagnesaemia and should therefore not be taken during therapy with calcitriol by patients on chronic renal dialysis.
Antacids, calcium carbonate
Antacids may decrease the bioavailability of calcium carbonate and prolong the renal elimination due to urine alkalinization
Antacids, cefpodoxime [2] ---> SmPC of [2] of eMC
The bioavailability is decreased by approximately 30% when cefpodoxime is administered with drugs which neutralize gastric pH or inhibit acid secretions. Therefore, such drugs should be taken 2 to 3 hours after cefpodoxime administration.
Antacids, cefuroxime [2] ---> SmPC of [2] of eMC
Drugs which reduce gastric acidity may result in a lower bioavailability of cefuroxime axetil compared with that of the fasting state and tend to cancel the effect of enhanced absorption after food.
Antacids, ceritinib [2] ---> SmPC of [2] of EMA
Gastric acid-reducing agents may alter the solubility of ceritinib and reduce its bioavailability as ceritinib demonstrates pH-dependent solubility and becomes poorly soluble as pH increases in vitro.
Antacids, chloroquine [2] ---> SmPC of [2] of eMC
Antacids may reduce the absorption of chloroquine, so should be taken well separated from chloroquine (at least four hours apart).
Antacids, chlorpromazine
The antacid can decrease the gastrointestinal absorption of phenothiazine
Antacids, cholic acid [2] ---> SmPC of [2] of EMA
The co-administration may decrease or prevent the absorption of cholic acid. Separate administration by at least 5 hours
Antacids, ciprofloxacin [2] ---> SmPC of [2] of eMC
The co-administration should be avoided because absorption of ciprofloxacin may be reduced.
Antacids, clarithromycin
The co-administration may increase the plasma levels of clarithromycin
Antacids, clodronate [2] ---> SmPC of [2] of eMC
Clodronate forms complexes with divalent metal ions, and therefore simultaneous administration with food, antacids and mineral supplements may impair absorption.
Antacids, clopidogrel [2] ---> SmPC of [2] of EMA
Antacids did not modify the extent of clopidogrel absorption.
Antacids, clopidogrel/acetylsalicylic acid [2] ---> SmPC of [2] of EMA
Antacids did not modify the extent of clopidogrel absorption.
Antacids, conjugated oestrogens/bazedoxifene [2] ---> SmPC of [2] of EMA
There were no significant pharmacokinetic interactions between bazedoxifene and antacids with aluminium
Antacids, cotrimoxazole
Antacid may decrease the absorption of cotrimoxazole
Antacids, crizotinib [2] ---> SmPC of [2] of EMA
The aqueous solubility of crizotinib is pH dependent, with low (acidic) pH resulting in higher solubility. Starting dose adjustment is not required when crizotinib is coadministered with agents that increase gastric pH
Antacids, cyproterone/ethinylestradiol
Antacids may decrease the plasma levels of ethinylestradiol by reduction of intestinal transit and hence may result in breakthrough bleeding and pregnancy.
Antacids, dabrafenib [2] ---> SmPC of [2] of EMA
Due to the theoretical risk that pH-elevating agents may decrease oral bioavailability and exposure to dabrafenib, these medicinal products that increase gastric pH should, if possible, be avoided during treatment with dabrafenib.
Antacids, daclatasvir [2] ---> SmPC of [2] of EMA
No clinically relevant effects on the pharmacokinetics of either medicinal product are expected when daclatasvir is coadministered with antacids
Antacids, dacomitinib [2] ---> SmPC of [2] of EMA
Local antacids and H2 receptor antagonists may be used if needed.
Antacids, darunavir/cobicistat [2] ---> SmPC of [2] of EMA
No mechanistic interaction expected based on theoretical consideration. Darunavir/cobicistat and antacids can be used concomitantly without dose adjustment.
Antacids, darunavir/cobicistat/emtricitabine/tenofovir alafenamide [2] ---> SmPC of [2] of EMA
No mechanistic interaction expected based on theoretical consideration. Symtuza and antacids can be used concomitantly without dose adjustment.
Antacids, dasatinib [2] ---> SmPC of [2] of EMA
Non-clinical data demonstrate that the solubility of dasatinib is pH-dependent. Antacids may be administered up to 2 hours prior to or 2 hours following dasatinib
Antacids, deflazacort
Antacids may reduce bioavailability of glucocorticoid; leave at least 2 hours between administration
Antacids, delafloxacin [2] ---> SmPC of [2] of EMA
Oral administration of delafloxacin with antacids containing aluminium or magnesium may substantially interfere with the absorption of delafloxacin. Delafloxacin should be taken at least 2 hours before or 6 hours after this agent.
Antacids, delapril
Antacids induce decreased bioavailability of ACE inhibitors.
Antacids, desloratadine/pseudoephedrine [2] ---> SmPC of [2] of EMA
The antacid increases the rate of pseudoephedrine absorption
Antacids, diacerein
Decreased absorption of diacerein. Separate administration by at least 2 hours
Antacids, dicycloverine
The co-administration may decrease the absorption of anticholinergic agent. The anticholinergic should be administered at least 1 hour before antacid
Antacids, digital glycosides ---> SmPC of [metildigoxin] of eMC
Decreased intestinal absorption of digitalis
Antacids, digoxin
Decreased digoxin absorption or increased elimination due to enterohepatic circulation interruption. Digoxin should be administered 2 hours before.
Antacids, dipotassium clorazepate
The co-administration may decrease the bioavailibility of clorazepate
Antacids, dipyridamole
The administration of antacids may reduce the efficacy of dipyridamole
Antacids, dolutegravir [2] ---> SmPC of [2] of EMA
Magnesium/aluminium-containing antacid should be taken well separated in time from the administration of dolutegravir (minimum 2 hours after or 6 hours before).
Antacids, dolutegravir/lamivudine
If Dovato is administered under fasting conditions, supplements or multivitamins containing calcium, iron or magnesium are recommended to be taken 2 hours after or 6 hours before Dovato
Antacids, dolutegravir/lamivudine [2] ---> SmPC of [2] of EMA
Dovato should not be co-administered with polyvalent cation-containing antacids. Polyvalent cation-containing antacids are recommended to be taken 2 hours after or 6 hours before Dovato
Antacids, dolutegravir/rilpivirine [2] ---> SmPC of [2] of EMA
Juluca should not be co-administered at the same time as antacids. These medicinal products are recommended to be administered 6 hours before or 4 hours after Juluca
Antacids, doravirine [2] ---> SmPC of [2] of EMA
No dose adjustment is required.
Antacids, doravirine/lamivudine/tenofovir disoproxil [2] ---> SmPC of [2] of EMA
No dose adjustment is required.
Antacids, doxycycline [2] ---> SmPC of [2] of eMC
Absorption of doxycycline may be impaired by concurrently administered with drugs containing aluminium, calcium, magnesium or other these cations; oral zinc, iron salts or bismuth preparations. Dosages should be maximally separated.
Antacids, duloxetine [2] ---> SmPC of [2] of EMA
Co-administration of YENTREVE with aluminium- and magnesium-containing antacids or with famotidine had no significant effect on the rate or extent of duloxetine absorption after administration of a 40 mg oral dose.
Antacids, efavirenz [2] ---> SmPC of [2] of EMA
Co-administration of efavirenz with medicinal products that alter gastric pH would not be expected to affect efavirenz absorption.
Antacids, elbasvir/grazoprevir [2] ---> SmPC of [2] of EMA
No dose adjustment is required.
Antacids, eltrombopag [2] ---> SmPC of [2] of EMA
Eltrombopag chelates with polyvalent cations. Eltrombopag should be taken at least 2 hours before or 4 hours after any products such as antacids, dairy products or mineral supplements containing polyvalent cations
Antacids, elvitegravir [2] ---> SmPC of [2] of EMA
Elvitegravir plasma concentrations are lower with antacids due to local complexation in the gastrointestinal tract. Separate administration by at least 4 hours
Antacids, elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide [2] ---> SmPC of [2] of EMA
Elvitegravir plasma concentrations are lower with antacids due to local complexation in the gastrointestinal tract and not to changes in gastric pH. It is recommended to separate Genvoya and antacid administration by at least 4 hours.
Antacids, elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil [2] ---> SmPC of [2] of EMA
Elvitegravir plasma concentrations are lower with antacids due to local complexation in the gastrointestinal tract. Separate administration by at least 4 hours
Antacids, elvitegravir/ritonavir
Decreased absorption of elvitegravir. Separate administration by at least 4 hours
Antacids, emtricitabine/rilpivirine/tenofovir alafenamide [2] ---> SmPC of [2] of EMA
Co-administration may cause significant decreases in rilpivirine plasma concentrations (reduced absorption, increase in gastric pH). Antacids should only be administered either at least 2 hours before or at least 4 hours after Odefsey.
Antacids, emtricitabine/rilpivirine/tenofovir disoproxil [2] ---> SmPC of [2] of EMA
The increase of gastric pH decreases absorption, plasma level and effect of rilpivirine. The antacid should be administered at least 2 h before or 4 h after rilpivirine
Antacids, entrectinib [2] ---> SmPC of [2] of EMA
No dose adjustments are required when entrectinib is co-administered with PPIs or other drugs that raise gastric pH (e.g., H2 receptor antagonists or antacids).
Antacids, eplerenone [2] ---> SmPC of [2] of eMC
Based on the results of a pharmacokinetic clinical study, are co-administered with eplerenone.
Antacids, erlotinib [2] ---> SmPC of [2] of EMA
Erlotinib is characterised by a decrease in solubility at pH above 5. Medicinal products that alter the pH of the upper Gastro-Intestinal (GI) tract may alter the solubility of erlotinib and hence its bioavailability.
Antacids, ethinyl estradiol ---> SmPC of [cyproterone/ethinylestradiol] of eMC
Antacids may decrease the plasma levels of ethinylestradiol by reduction of intestinal transit and hence may result in breakthrough bleeding and pregnancy.
Antacids, ethinylestradiol/gestodene
Antacids (overall those with magnesium) may decrease ethinylestradiol plasma concentration by decreasing the intestinal transit
Antacids, etidronate [2] ---> SmPC of [2] of eMC
Vitamins with mineral supplements such as iron, calcium supplements, laxatives containing magnesium, or antacids containing calcium or aluminium should not be taken within two hours of dosing etidronate disodium.
Antacids, etoricoxib [2] ---> SmPC of [2] of eMC
Antacids do not affect the pharmacokinetics of etoricoxib to a clinically relevant extent.
Antacids, ezetimibe [2] ---> SmPC of [2] of eMC
Concomitant antacid administration decreased the rate of absorption of ezetimibe but had no effect on the bioavailability of ezetimibe. This decreased rate of absorption is not considered clinically significant.
Antacids, ezetimibe/atorvastatin [2] ---> SmPC of [2] of eMC
Concomitant antacid administration decreased the rate of absorption of ezetimibe but had no effect on the bioavailability of ezetimibe. This decreased rate of absorption is not considered clinically significant.
Antacids, ezetimibe/simvastatine [2] ---> SmPC of [2] of eMC
Concomitant antacid administration decreased the rate of absorption of ezetimibe but had no effect on the bioavailability of ezetimibe. This decreased rate of absorption is not considered clinically significant.
Antacids, famotidine
Decreased absorption of famotidine. Famotidine should be taken 1 to 2 hours before antacid.
Antacids, febuxostat [2] ---> SmPC of [2] of EMA
Febuxostat may be taken without regard to antacid use.
Antacids, flavoxate
Decreased flavoxate effect
Antacids, fluphenazine
The co-administration of antacids and fluphenazine may decrease the absorption of fluphenazine
Antacids, folic acid
Drugs that may adversely affect the absorption or metabolism of folic acid may cause statuses of folate deficiency
Antacids, fosamprenavir/ritonavir ---> SmPC of [fosamprenavir] of EMA
The increase in gastric pH decreases the fosamprenavir absorption. No dosage adjustment necessary
Antacids, fosinopril [2] ---> SmPC of [2] of eMC
Antacids may impair absorption of fosinopril. Administration of fosinopril sodium and antacids should be separated by at least 2 hours.
Antacids, gabapentin [2] ---> SmPC of [2] of eMC
Coadministration of gabapentin with antacids containing aluminium and magnesium, reduces gabapentin bioavailability up to 24%. It is recommended that gabapentin is taken about two hours following any such antacid administration.
Antacids, gefitinib [2] ---> SmPC of [2] of EMA
Substances that cause significant sustained elevation in gastric pH may reduce gefitinib plasma concentrations and thereby reduce the efficacy of gefitinib.
Antacids, glasdegib [2] ---> SmPC of [2] of EMA
Concomitant administration of glasdegib with acid-reducing agents (including PPIs, H2-receptor antagonists, and locally acting antacids) is permitted.
Antacids, glucocorticoids
Antacids may reduce bioavailability of glucocorticoid; leave at least 2 hours between administration
Antacids, hydroxychloroquine [2] ---> SmPC of [2] of eMC
Antacids may reduce absorption of hydroxychloroquine so it is advised that a 4 hour interval be observed between hydroxychloroquine and antacid dosaging.
Antacids, imidapril [2] ---> SmPC of [2] of eMC
Antacids may induce decreased bioavailability of imidapril.
Antacids, indometacin
Decreased absorption rate of indometacin
Antacids, isoniazid
Decreased isoniazid absorption. Administer antacid at least 2 hours after
Antacids, itraconazol [2] ---> SmPC of [2] of eMC
Medicinal products that reduce the gastric acidity impair the absorption of itraconazole. It is recommended that these medicinal products be used with caution when coadministered with itraconazole
Antacids, ketoconazole [2] ---> SmPC of [2] of EMA
Acid-neutralising medicines should not be administered for at least 2 hours after the intake of ketoconazole.
Antacids, ketoprofen
Antacid decreases the absorption of NSAID. Separate administration by at least 2 hours
Antacids, lactitol
Decrease of the stool acidifying effect of lactitol. The co-administration is not recommended
Antacids, lactulose
Weakening of the laxative effect
Antacids, lansoprazole [2] ---> SmPC of [2] of eMC
Antacids may decrease the bioavailability of lansoprazole. Lansoprazole should be given at least 1 hour after taking the antacid
Antacids, lapatinib [2] ---> SmPC of [2] of EMA
The solubility of lapatinib is pH-dependent. Concomitant treatment with substances that increase gastric pH should be avoided, as lapatinib solubility and absorption may decrease.
Antacids, ledipasvir/sofosbuvir [2] ---> SmPC of [2] of EMA
Ledipasvir solubility decreases as pH increases. Medicinal products that increase gastric pH are expected to decrease concentration of ledipasvir. It is recommended to separate the administration by 4 hours.
Antacids, levetiracetam [2] ---> SmPC of [2] of EMA
No data on the influence of antacids on the absorption of levetiracetam are available.
Antacids, levodopa ---> SmPC of [levodopa/benserazide] of eMC
Concomitant use of antacids with levodopa/benserazide decreases the absorption of levodopa
Antacids, levodopa/benserazide
Concomitant use of antacids with levodopa/benserazide decreases the absorption of levodopa
Antacids, levothyroxine
The co-administration decreases the absorption of levothyroxine. Separate administration by at least 2 hours
Antacids, lorazepam [2] ---> SmPC of [2] of eMC
Concurrent use of antacids may delay absorption of lorazepam
Antacids, lymecycline [2] ---> SmPC of [2] of eMC
The absorption of tetracyclines may be affected by the simultaneous administration of antacids. These products should not be taken within 2 hours before or after taking lymecycline
Antacids, metformin/saxagliptin/dapagliflozin [2] ---> SmPC of [2] of EMA
In studies conducted in healthy subjects, neither the pharmacokinetics of saxagliptin nor its major metabolite were meaningfully altered
Antacids, methylphenidate
Decreased absorption of methylphenidate
Antacids, metildigoxin
Decreased intestinal absorption of digitalis. Metildigoxin should be taken 2 hours before
Antacids, minocycline [2] ---> SmPC of [2] of eMC
Absorption of minocycline is impaired by the concomitant administration. Dosages should be maximally separated.
Antacids, misoprostol
Antacids may decrease the bioavailability of misoprostol
Antacids, moexipril
Decreased bioavailability of ACE inhibitors may occur.
Antacids, moxifloxacin [2] ---> SmPC of [2] of eMC
An interval of about 6 hours should be left between administration of agents containing bivalent or trivalent cations and administration of moxifloxacin.
Antacids, multivitamin supplements
Antacids are known to interfere with the absorption of vitamins.
Antacids, mycophenolate mofetil [2] ---> SmPC of [2] of EMA
Decreased mycophenolic acid (MPA) exposure has been observed when antacids, such as magnesium and aluminium hydroxides, and PPIs, including lansoprazole and pantoprazole, were administered with mycophenolate mofetil.
Antacids, naproxen
Antacid decreases the absorption of NSAID. Separate administration by at least 2 hours
Antacids, neratinib [2] ---> SmPC of [2] of EMA
If an antacid is taken, separate the dosing of Nerlynx and the antacid by at least 3 hours.
Antacids, nevirapine [2] ---> SmPC of [2] of EMA
The absorption of nevirapine is not affected by food, antacids or medicinal products which are formulated with an alkaline buffering agent.
Antacids, nilotinib [2] ---> SmPC of [2] of EMA
If necessary, an antacid may be administered approximately 2 hours before or approximately 2 hours after the dose of Tasigna.
Antacids, norfloxacin
Decreased absorption of quinolone. The quinolone should be administered 2 hours before or 4 hours after the administration of the other active principle.
Antacids, nortriptyline
Possible decrease of plasma levels of nortriptyline
Antacids, NSAID
Antacid decreases the absorption of NSAID. Separate administration by at least 2 hours
Antacids, ofloxacin [2] ---> SmPC of [2] of eMC
The co-administration may decrease the absorption of ofloxacin. Separate administration by at least 2 hours
Antacids, olanzapine [2] ---> SmPC of [2] of EMA
Fluoxetine (a CYP2D6 inhibitor), single doses of antacid (aluminium, magnesium) or cimetidine have not been found to significantly affect the pharmacokinetics of olanzapine.
Antacids, olmesartan
After treatment with antacid, a modest reduction in bioavailability of olmesartan was observed.
Antacids, olmesartan medoxomil [2] ---> SmPC of [2] of eMC
After treatment with antacid (aluminium magnesium hydroxide), a modest reduction in bioavailability of olmesartan was observed.
Antacids, olmesartan medoxomil/amlodipine [2] ---> SmPC of [2] of eMC
After treatment with antacid, a modest reduction in bioavailability of olmesartan was observed.
Antacids, oxytetracycline [2] ---> SmPC of [2] of eMC
Antacids containing aluminium, calcium, iron, magnesium or zinc may impair absorption of oxytetracycline. Allow 2 to 3 hours between doses of oxytetracycline and antacids.
Antacids, palbociclib [2] ---> SmPC of [2] of EMA
Given the reduced effect on gastric pH of H2-receptor antagonists and local antacids compared to PPIs, no clinically relevant effect of H2-receptor antagonists or local antacids on palbociclib exposure is expected when palbociclib is taken with food.
Antacids, pazopanib [2] ---> SmPC of [2] of EMA
Co-administration of pazopanib with medicines that increase gastric pH should be avoided.
Antacids, pefloxacine
The co-administration of antacids may decrease the absorption of quinolones due to formation of insoluble complexes. Separate administration by 3-4 hours
Antacids, penicillamine
Oral absorption of penicillamine may be reduced by concomitant administration of antacids
Antacids, perindopril
The co-administration may reduce the absorption of ACE inhibitor. Therefore, at least 2 hours should elapse between the administration of each other.
Antacids, perphenazine
Antacids may decrease the absorption of perphenazine.
Antacids, phenothiazines ---> SmPC of [alimemazine] of eMC
The antacid can decrease the gastrointestinal absorption of phenothiazine
Antacids, pipotiazine
The co-administration may decrease the absorption of phenothiazine. Separate administration by at least 2 hours
Antacids, piroxicam [2] ---> SmPC of [2] of eMC
Concomitant administration of antacids had no effect on piroxicam plasma levels.
Antacids, pravastatine [2] ---> SmPC of [2] of eMC
In interaction studies, no statistically significant differences in bioavailability were observed when pravastatin was administered with antacids (when given one hour prior to pravastatin)
Antacids, pravastatine/fenofibrate [2] ---> SmPC of [2] of EMA
In interaction studies, no statistically significant differences in bioavailability were observed when pravastatin was administered with antacids (when given one hour prior to pravastatin)
Antacids, prednisolone [2] ---> SmPC of [2] of eMC
Antacids can reduce the absorption of prednisolone if given in high doses. Indigestion remedies should not be taken at the same time of day as prednisolone.
Antacids, pregnancy
Use of antacids should be avoided in the first trimester of pregnancy.
Antacids, procyclidine
The co-administration may decrease the absorption of anticholinergic agent. Procyclidine should be administered at least 1 hour before antacid
Antacids, proglumetacine
Antacid decreases the absorption of NSAID. Separate administration by at least 2 hours
Antacids, proguanil
Antacids may reduce the absorption of proguanil, so should be taken at least 2-3 hours apart.
Antacids, promazine
Antacids and kaolin may reduce absorption of phenothiazines
Antacids, promethazine ---> SmPC of [alimemazine] of eMC
The antacid can decrease the gastrointestinal absorption of phenothiazine
Antacids, propranolol
Decrease of propranolol effect
Antacids, prulifloxacin ---> SmPC of [norfloxacin] of eMC
Decreased absorption of quinolone. The quinolone should be administered 2 hours before or 4 hours after the administration of antacid
Antacids, pyrimethamine
In vitro data suggest that antacid salts reduce the absorption of pyrimethamine.
Antacids, quinapril [2] ---> SmPC of [2] of eMC
Antacids may decrease the bioavailability of quinapril
Antacids, quinolones ---> SmPC of [norfloxacin] of eMC
Decreased absorption of quinolone. The quinolone should be administered 2 hours before or 4 hours after the administration of antacid
Antacids, rabeprazole [2] ---> SmPC of [2] of eMC
In clinical trials, antacids were used concomitantly with the administration of rabeprazole and, in a specific drug-drug interaction study, no interaction with liquid antacids was observed.
Antacids, ranitidine
Decreased ranitidine absorption. Take ranitidine 2 hours before antacid
Antacids, rifabutin
Antacids should be taken 3 hours after taking rifabutin in order to avoid interactions
Antacids, rifampicin
The antacid decreases the absorption of rifampicin. Rifampicin should be given at least 1 hour before the ingestion of antacids
Antacids, rilpivirine [2] ---> SmPC of [2] of EMA
The increase of gastric pH decreases absorption, plasma level and effect of rilpivirine. The antacid should be administered at least 2 h before or 4 h after rilpivirine
Antacids, riociguat [2] ---> SmPC of [2] of EMA
Riociguat exhibits a reduced solubility at neutral pH vs. acidic medium. Co-medication of drugs increasing the upper GI pH may decrease oral riociguat bioavailability. Antacids should be taken at least 2 hours before, or 1 hour after riociguat.
Antacids, roflumilast [2] ---> SmPC of [2] of EMA
Co-administration with an antacid (combination of aluminium hydroxide and magnesium hydroxide) did not alter the absorption or pharmacokinetics of roflumilast or its N-oxide.
Antacids, rosuvastatin [2] ---> SmPC of [2] of eMC
The simultaneous dosing of rosuvastatin with an antacid suspension containing magnesium hydroxide resulted in a decrease in rosuvastatin plasma concentration of approximately 50%.
Antacids, rufloxacin ---> SmPC of [norfloxacin] of eMC
Decreased absorption of quinolone. The quinolone should be administered 2 hours before or 4 hours after the administration of antacid
Antacids, salicylates ---> SmPC of [acetylsalicylic acid] of eMC
Antacids may increase the salicylate excretion by alkalinization of urine
Antacids, sildenafil [2] ---> SmPC of [2] of EMA
Single doses of antacid (magnesium hydroxide/aluminium hydroxide) did not affect the bioavailability of sildenafil.
Antacids, simeprevir [2] ---> SmPC of [2] of EMA
No clinically relevant drug-drug interaction is expected. No dose adjustment is required
Antacids, sodium fluoride
Decreased absorption of sodium fluoride. It is recommended to administer the two substances at least 3 hours apart.
Antacids, sofosbuvir/velpatasvir [2] ---> SmPC of [2] of EMA
Increase in gastric pH. It is recommended to separate antacid and Epclusa administration by 4 hours.
Antacids, sofosbuvir/velpatasvir/voxilaprevir [2] ---> SmPC of [2] of EMA
Increase in gastric pH decreases velpatasvir solubility. It is recommended to separate antacid and Vosevi administration by 4 hours.
Antacids, strontium ranelate [2] ---> SmPC of [2] of EMA
It is preferable to take antacids at least 2 hours after strontium ranelate
Antacids, sucralfate ---> SmPC of [algeldrate/magnesium hydroxide] of eMC
The co-administration may decrease the effect of sucralfate. It is recommended to administer the two substances at least 2-4 hours apart.
Antacids, sulfadiazine
Decreased absorption of sulfonamide
Antacids, sulphamides
Decreased absorption of sulfonamide
Antacids, sulphonamides
Decreased absorption of sulfonamide
Antacids, sulpiride [2] ---> SmPC of [2] of eMC
The absorption of sulpiride is decreased after co-administration with antacids. Therefore, sulpiride should be administered 2 hours before antacid
Antacids, sultiame
The antacid may adsorb sultiame and decrease its plasma levels
Antacids, talazoparib [2] ---> SmPC of [2] of EMA
Population PK analysis indicates that co-administration of acid-reducing agents had no significant impact on the absorption of talazoparib.
Antacids, tetracyclines ---> SmPC of [doxycycline] of eMC
Decreased absorption of tetracycline. It is recommended to administer the two substances at least 3 hours apart.
Antacids, theophylline
The antacid may decrease the absorption of theophylline
Antacids, thiamine
Decreased absorption of thiamine
Antacids, thioridazine
The antacid can decrease the gastrointestinal absorption of oral administered thioridazine
Antacids, ticlopidine
The co-administration of ticlopidine and antacids decreases the plasma levels of ticlopidine about 20-30%.
Antacids, trandolapril [2] ---> SmPC of [2] of eMC
Antacids may cause reduced bioavailability of ACE inhibitors.
Antacids, trandolapril/verapamil [2] ---> SmPC of [2] of eMC
Antacids induce decreased bioavailability of ACE inhibitors.
Antacids, triamcinolone
Antacids may reduce bioavailability of glucocorticoid; leave at least 2 hours between administration
Antacids, trientine [2] ---> SmPC of [2] of EMA
Although there is no evidence that calcium or magnesium antacids alter the efficacy of trientine, it is good practice to separate their administration.
Antacids, trifluoperazine ---> SmPC of [alimemazine] of eMC
Antacids can reduce the absorption of phenothiazines.
Antacids, trimethoprim/sulfamethoxazol
Antacid may decrease the absorption of cotrimoxazole
Antacids, ulipristal [2] ---> SmPC of [2] of EMA
The effect of medicinal products that increase gastric pH is not expected to be of clinical relevance for daily administration of ulipristal acetate tablets.
Antacids, upadacitinib [2] ---> SmPC of [2] of EMA
Methotrexate and pH modifying medicinal products (e.g., antacids or proton pump inhibitors) have no effect on upadacitinib plasma exposures.
Antacids, urinary acidifying agents
The antacid may alkalize the urine and counteract the effect of the urinary acidifying
Antacids, vardenafil [2] ---> SmPC of [2] of EMA
The pharmacokinetics of vardenafil (20 mg) was not affected by single doses of antacid (magnesium hydroxide/aluminium hydroxide).
Antacids, venetoclax [2] ---> SmPC of [2] of EMA
Based on population pharmacokinetic analysis, gastric acid reducing agents (e.g., proton pump inhibitors, H2-receptor antagonists, antacids) do not affect venetoclax bioavailability.
Antacids, vitamin B1
Decreased absorption of thiamine
Antacids, vitamin C ---> SmPC of [ascorbic acid] of eMC
The concomitant use of aluminium-containing antacids with ascorbic acid may increase the aluminium absorption and cause toxicity. The combination is not recommended
Antacids, ziprasidone
Repeated administration of magnesium and aluminium containing antacids or cimetidine after eating had no significant effect on ziprasidone pharmacokinetics
Antacids, zofenopril
Antacids reduce the bioavailability of ACE inhibitors.